DocGo Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
DocGo s intäkter har minskat med en genomsnittlig årlig takt på -41.2%, medan Healthcare -branschen såg intäkter på växande 9.9% årligen. Intäkterna har varit växande med en genomsnittlig takt på 17.2% per år.
Viktig information
-41.23%
Tillväxttakt i vinsten
-37.57%
Tillväxttakt för EPS
| Healthcare Tillväxt i branschen | 8.50% |
| Intäkternas tillväxttakt | 17.21% |
| Avkastning på eget kapital | -156.01% |
| Nettomarginal | -56.61% |
| Nästa resultatuppdatering | 11 May 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
DCGO: Transport EBITDA Outlook Will Drive Future Upside Potential
Analysts recently trimmed their DocGo price targets, with cuts such as Stifel's move from $4.00 to $2.50, citing mixed Q4 results, modestly higher 2026 transport guidance, and updated expectations for growth, margins, and P/E assumptions. Analyst Commentary Bullish analysts acknowledge the recent price target cuts but still point to several areas they see as supportive for DocGo's valuation and long term execution story.
DCGO: Transport EBITDA And 2026 Guidance Will Drive Future Upside Potential
Narrative Update Analysts have nudged their price expectations for DocGo lower, trimming aggregate targets by around $0.10 as they factor in mixed Q4 results, modestly higher 2026 transport guidance, and updated views on margins, growth, and future P/E multiples. Analyst Commentary Recent Street commentary on DocGo is mixed, with some analysts focusing on potential value in the transport segment and others reacting to lower price targets and Q4 variability.DCGO: Transport EBITDA Outlook Will Support Future Upside Potential
Narrative Update The analyst price target for DocGo has been reduced from $4.00 to $2.50, as analysts factor in mixed Q4 results while crediting modestly higher 2026 transport guidance and the view that the transport unit alone could potentially support proceeds above the current share price. Analyst Commentary Recent research reflects a more cautious stance on DocGo, with the price target reduced to US$2.50 while still crediting specific strengths in the transport segment.
DCGO: Future Returns Will Rely On Expanding Telehealth Weight Loss Services
Analysts have trimmed their price targets on DocGo to reflect slightly softer revenue growth assumptions, along with somewhat stronger profit margin and future P/E expectations, resulting in only a modest adjustment to their overall valuation view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the $1.00 minimum bid price requirement.DCGO: Buyback Extension And Telehealth Expansion Will Support Future Upside
Analysts have trimmed their price targets on DocGo to $2.50, citing slightly higher discount rate assumptions, a modestly softer profit margin outlook, and a higher future P/E multiple as key drivers of the revised view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the minimum US$1.00 bid price requirement, triggering a 180 day window until July 27, 2026 to regain compliance before potential further action is considered (Delistings).DCGO: Future Returns Will Rely On Expanding Longitudinal Virtual Weight Loss Care
Analysts have slightly reduced their price target on DocGo, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. This adjustment signals a more cautious stance on the company’s risk and earnings profile.DCGO: Buyback Extension And M&A Pipeline Will Support Future Upside
Analysts have trimmed their price target on DocGo to reflect a fair value shift from about $3.08 to roughly $2.50. The change reflects updated assumptions around revenue contraction, slightly higher required returns, modestly better profit margins, and a lower future P/E multiple.DCGO: Future Returns Will Depend On Expanding Longitudinal Care Partnerships
Analysts have made a small upward tweak to their price target on DocGo, reflecting slightly more constructive assumptions around revenue growth and long term profit margins, while keeping the projected P/E and discount rate almost unchanged. What's in the News Robbins Geller Rudman & Dowd LLP announced a proposed US$12.5 million cash settlement in the DocGo securities class action, subject to court approval at a hearing scheduled for March 24, 2026 in the Southern District of New York (Lawsuits & Legal Issues).DCGO: Future Returns Will Depend On Longitudinal Care And Maturing Revenue Mix
Analysts have nudged up their price target on DocGo by a modest amount, citing slightly higher long term profit margin expectations and a marginally richer future earnings multiple. Together, these factors support a small increase in estimated fair value.DCGO: Future Returns Will Depend On New Longitudinal Care Contracts
Analysts have lowered their price target on DocGo from approximately 1.60 dollars to 1.00 dollars, citing a higher required discount rate and a reduced valuation multiple, despite modest improvements in the projected revenue trajectory and profit margins. What's in the News DocGo signaled an active mergers and acquisitions strategy, highlighting its ability to acquire traditional health care assets and layer on its technology and mobile health capabilities to support long-term growth and shareholder value (company commentary) The company provided updated guidance, forecasting 2025 revenue of 315 million to 320 million dollars, including 68 million to 70 million dollars from migrant-related contracts, and 2026 revenue of 280 million to 300 million dollars with no migrant-related revenue (corporate guidance) DocGo recorded a goodwill impairment charge of approximately 8.7 million dollars in the third quarter of 2025, reflecting a write-down of acquired assets (company filing) DocGo announced a new Longitudinal Care Services program with a California-based insurer, targeting 10,000 under-engaged members with combined telehealth and in-home clinical services starting in the fourth quarter (client announcement) The company is expanding its partnership with a national insurer in New Mexico, launching care gap closure and planned primary care services for 10,000 Turquoise Care members through at-home visits and chronic care support (client announcement) Valuation Changes The fair value estimate has fallen significantly from approximately $1.60 to $1.00 per share.Benign Growth For DocGo Inc. (NASDAQ:DCGO) Underpins Its Share Price
Sep 26
DocGo Inc. (NASDAQ:DCGO) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
May 16Is It Too Late To Consider Buying DocGo Inc. (NASDAQ:DCGO)?
Apr 16We Like The Quality Of DocGo's (NASDAQ:DCGO) Earnings
Mar 06These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Mar 01Subdued Growth No Barrier To DocGo Inc. (NASDAQ:DCGO) With Shares Advancing 33%
Feb 11
Innovative Health Initiatives Promise Growth Amid Analysts' Concerns Over Future Earnings And Margins
Strategic partnerships with virtual-only providers and operational efficiency improvements indicate a comprehensive approach to expanding health solutions and improving margins.DocGo Inc. (NASDAQ:DCGO) Doing What It Can To Lift Shares
Aug 05At US$3.40, Is DocGo Inc. (NASDAQ:DCGO) Worth Looking At Closely?
Jul 17These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Jun 11DocGo: Upside Remains Attractive After Share Price Decline
Mar 20Does DocGo (NASDAQ:DCGO) Have A Healthy Balance Sheet?
Feb 13DocGo: Good Performance, Trust Issues
Feb 05Why DocGo Inc. (NASDAQ:DCGO) Could Be Worth Watching
Jan 25Fewer Investors Than Expected Jumping On DocGo Inc. (NASDAQ:DCGO)
Jan 04Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur DocGo tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Dec 25 | 322 | -182 | 159 | 14 |
| 30 Sep 25 | 368 | -52 | 151 | 13 |
| 30 Jun 25 | 436 | -18 | 147 | 13 |
| 31 Mar 25 | 521 | -1 | 150 | 13 |
| 31 Dec 24 | 617 | 20 | 157 | 12 |
| 30 Sep 24 | 695 | 31 | 163 | 11 |
| 30 Jun 24 | 743 | 30 | 170 | 11 |
| 31 Mar 24 | 703 | 22 | 164 | 11 |
| 31 Dec 23 | 624 | 7 | 153 | 11 |
| 30 Sep 23 | 534 | 7 | 142 | 9 |
| 30 Jun 23 | 452 | 6 | 127 | 8 |
| 31 Mar 23 | 436 | 20 | 122 | 6 |
| 31 Dec 22 | 441 | 35 | 117 | 5 |
| 30 Sep 22 | 453 | 50 | 110 | 5 |
| 30 Jun 22 | 435 | 50 | 107 | 4 |
| 31 Mar 22 | 387 | 36 | 96 | 4 |
| 31 Dec 21 | 319 | 24 | 84 | 3 |
| 30 Sep 21 | 229 | -4 | 66 | 3 |
| 30 Jun 21 | 170 | -10 | 54 | 2 |
| 31 Mar 21 | 130 | -10 | 45 | 2 |
| 31 Dec 20 | 94 | -14 | 39 | 1 |
| 31 Dec 19 | 48 | -20 | 29 | 1 |
Kvalitetsintäkter: DCGO är för närvarande olönsam.
Växande vinstmarginal: DCGO är för närvarande olönsam.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: DCGO är olönsam och förlusterna har ökat under de senaste 5 åren i en takt av 41.2% per år.
Accelererande tillväxt: Det går inte att jämföra DCGO s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt
Resultat vs industri: DCGO är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Healthcare branschen ( 17.2% ).
Avkastning på eget kapital
Hög ROE: DCGO har en negativ avkastning på eget kapital ( -156.01% ), eftersom det för närvarande är olönsamt.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/03 18:12 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
DocGo Inc. bevakas av 7 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Sarah James | Barclays |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |